• European Commission granted marketing authorization for Sotyktu (deucravacitinib) to treat active psoriatic arthritis in adults with inadequate response or intolerance to prior DMARD therapy.
• Label covers use as monotherapy or with methotrexate; drug is once-daily oral TYK2 inhibitor.
• Approval backed by Phase 3 POETYK PsA-1 and PsA-2 trials, which met primary endpoint with ACR20 responses at Week 16 versus placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 202605080659BIZWIRE_USPR_____20260507_BW663929) on May 08, 2026, and is solely responsible for the information contained therein.